Literature DB >> 7340988

Blood levels of o,p'-DDD following administration in various vehicles after a single dose and during long-term treatment.

A J Moolenaar, H van Slooten, A P van Seters, D Smeenk.   

Abstract

Plasma levels of o,p'-DDD were measured after ingestion of a single oral dose. At the onset of therapy o,p'-DDD was administered as commercially available tablets and granules and in milk, chocolate, and an oil emulsion to 9, 12, 14, 10, and 6 patients, respectively. Following administration in chocolate, emulsion, and milk significantly higher mean plasma levels were recorded in the first 5- and 10-h periods than after tablets. Granules gave significantly lower plasma levels than all other forms. Plasma levels were also measured during maintenance therapy, when a total of 200 g o,p'-DDD was administered to 22 patients with adrenocortical carcinoma. The plasma disappearance rate after termination of long-term therapy was found to be between 18 and 159 days. The recovery of o,p'-DDD from faeces was about five times higher after ingestion of tablets than after administration in oil emulsion and milk. As far as the rapid increase in plasma levels and patient compliance are concerned, the best results were obtained with the milk powder mixture.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7340988     DOI: 10.1007/bf00258213

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  Studies of the pharmacology of o,p'DDD in man.

Authors:  R H MOY
Journal:  J Lab Clin Med       Date:  1961-08

2.  TREATMENT OF A CASE OF NONTUMOROUS CUSHING'S SYNDROME WITH O,P'DDD.

Authors:  J BAR-HAY; A BENDERLY; G RUMNEY
Journal:  Pediatrics       Date:  1964-02       Impact factor: 7.124

3.  Estimation of o,p'-DDD in plasma by gas-liquid chromatography.

Authors:  A J Moolenaar; J W Niewint; I T Oei
Journal:  Clin Chim Acta       Date:  1977-04-15       Impact factor: 3.786

4.  Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases.

Authors:  J P Luton; J A Mahoudeau; P Bouchard; P Thieblot; M Hautecouverture; D Simon; M H Laudat; Y Touitou; H Bricaire
Journal:  N Engl J Med       Date:  1979-03-01       Impact factor: 91.245

5.  Treatment of Cushing's disease. Correction of hypercortisolism by o,p'DDD without induction of aldosterone deficiency.

Authors:  T E Temple; D J Jones; G W Liddle; R N Dexter
Journal:  N Engl J Med       Date:  1969-10-09       Impact factor: 91.245

6.  Mitotane use in inoperable adrenal cortical carcinoma.

Authors:  J A Lubitz; L Freeman; R Okun
Journal:  JAMA       Date:  1973-03-05       Impact factor: 56.272

7.  Adrenal cortical carcinoma. Clinical features of 138 patients.

Authors:  A M Hutter; D E Kayhoe
Journal:  Am J Med       Date:  1966-10       Impact factor: 4.965

8.  Aromatic hydroxylation and alkyl oxidation in metabolism of mitotane (o,p'-DDD) in humans.

Authors:  V D Reif; J E Sinsheimer; J C Ward; D E Schteingart
Journal:  J Pharm Sci       Date:  1974-11       Impact factor: 3.534

9.  o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.

Authors:  T F Hogan; D L Citrin; B M Johnson; S Nakamura; T E Davis; E C Borden
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

10.  The toxicity and toxic manifestations of 2,2-bis-(p-chlorophenyl)-1,1,1-trichloroethane (DDT) as influenced by chemical changes in the molecule; a contribution to the relation between chemical constitution and toxicological action.

Authors:  W F VON OETTINGEN; N E SHARPLESS
Journal:  J Pharmacol Exp Ther       Date:  1946-12       Impact factor: 4.030

  10 in total
  12 in total

1.  Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.

Authors:  Matthias Kroiss; Silviu Sbiera; Sabine Kendl; Max Kurlbaum; Martin Fassnacht
Journal:  Horm Cancer       Date:  2016-09-08       Impact factor: 3.869

Review 2.  Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.

Authors:  Irina Veytsman; Lynnette Nieman; Tito Fojo
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

3.  o,p'-DDD (mitotane) treatment for Cushing's syndrome: adrenal drug concentration and inhibition in vitro of steroid synthesis.

Authors:  Y Touitou; A J Moolenaar; A Bogdan; A Auzéby; J P Luton
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  O,p'-DDD (mitotane) levels in plasma and tissues during chemotherapy and at autopsy.

Authors:  H von Slooten; A P van Seters; D Smeenk; A J Moolenaar
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  Quercetin-Rich Extracts from Onions (Allium cepa) Play Potent Cytotoxicity on Adrenocortical Carcinoma Cell Lines, and Quercetin Induces Important Anticancer Properties.

Authors:  Alan A Veiga; Ana Carolina Irioda; Bassam F Mogharbel; Sandro J R Bonatto; Lauro M Souza
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-16

6.  The role of calcium ions and bile salts on the pancreatic lipase-catalyzed hydrolysis of triglyceride emulsions stabilized with lecithin.

Authors:  F J Alvarez; V J Stella
Journal:  Pharm Res       Date:  1989-06       Impact factor: 4.200

7.  Plasma level monitoring of mitotane (o,p'-DDD) and its metabolite (o,p'-DDE) during long-term treatment of Cushing's disease with low doses.

Authors:  R Benecke; E Keller; B Vetter; R A de Zeeuw
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

8.  Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at Three Months?

Authors:  Yoann Cazaubon; Yohann Talineau; Catherine Feliu; Céline Konecki; Jennifer Russello; Olivier Mathieu; Zoubir Djerada
Journal:  Pharmaceutics       Date:  2019-10-31       Impact factor: 6.321

9.  Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.

Authors:  H R Haak; J Hermans; C J van de Velde; E G Lentjes; B M Goslings; G J Fleuren; H M Krans
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

10.  Mitotane (op'DDD) restores growth and puberty in nine children with Cushing's disease.

Authors:  Emmanuelle Motte; Anya Rothenbuhler; Stephan Gaillard; Najiba Lahlou; Cécile Teinturier; Régis Coutant; Agnès Linglart
Journal:  Endocr Connect       Date:  2018-12       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.